Today, seeking therapeutic relief for brain disorders includes compromise. Currently available treatment options offer limited efficacy for patients and bring with them significant side effects. MapLight is on a mission to change this paradigm.
The brain – with its 86 billion nerve cells – is complex. But flooding it with generalized therapeutics to treat highly specific symptoms cannot continue to be the only answer.
MapLight’s renowned neuroscientists have built a unique discovery platform that combines cutting edge technologies to uncover the individual circuits that misfire in brain disorders. These technologies target those circuits, enabling us to develop innovative therapeutics with the potential to improve the treatment of multiple CNS conditions.
MapLight’s novel approach combines proprietary, patented innovations such as optogenetics, STARmap and transcriptomics. Using these strategies, MapLight has developed a strong pipeline of innovative therapeutics.
MapLight’s compounds in clinical development demonstrate promise for multiple indications and disorders, including schizophrenia, Alzheimer’s disease psychosis, and autism spectrum disorder. MapLight’s preclinical pipeline includes compounds for the potential treatment of Parkinson’s disease, hyperactivity, and impulsivity.
© MapLight | Privacy | Expanded Access Policy | Cookie Policy
